Affiliation:
1. Institut National de la Santé et de la Recherche Médicale Inserm Unit 1121 Biomaterials and Bioengineering Centre de Recherche en Biomédecine de Strasbourg Strasbourg 67000 France
2. Faculté de Chirurgie Dentaire Université de Strasbourg Strasbourg 67000 France
3. Centre de Recherche en Biomédecine de Strasbourg SPARTHA Medical Strasbourg 67000 France
4. Centre national de la recherche scientifique (CNRS) Laboratoire de Conception et Application de Molécules Bioactives UMR 7199 Faculté de Pharmacie Université de Strasbourg Illkirch 67401 France
Abstract
ε‐poly‐l‐lysine (ε‐PLL) is a natural polypeptide/polycation originating from bacteria. Thanks to its antifungal and antibacterial properties, it is the subject of extensive research in the food and medical industries. ε‐PLL is also used to develop biomaterials in a broad range of applications, such as drug delivery, wound healing, or antimicrobial coatings. Indeed, loading ε‐PLL inside nanoparticles, functionalizing implant surfaces with ε‐PLL, or developing hydrogels based on reactions between ε‐PLL and other polymers can improve the materials properties, leading to biocompatible, antibacterial, and antifungal systems. These characteristics are necessary not only for the development of biomaterials, for their integrity in a biological environment, but also for improving the performances of medical devices. Moreover, ε‐PLL can be used as an alternative to antibiotics as its mechanism of action reduces the bacterial resistance risk compared with antibiotics. Finally, “smart” systems using ε‐PLL may be developed, with controllable material degradation or drug delivery via pH or temperature variations. This review sought to gather the latest research on the development of antimicrobial biomaterials based on the ε‐PLL polypeptide.
Funder
H2020 European Research Council
Agence Nationale de la Recherche
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献